Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$67.73
−$0.80 · -1.17%
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Previous close
$67.73
−$0.80 · -1.17%
Pre-market
$67.70
−$0.03 · -0.04%
Oct 9, 4:00 AM ET
Regular session · ET · Market data may be delayed.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Day range
Current $67.73
52-week range
Current $67.73
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
76
Undervalued
Sentiment
43
Mixed
Risk
71
High Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Day range
Current $67.73
52-week range
Current $67.73
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 427.54M USD | 305.45M USD | 202.57M USD | 234.69M USD | 212.2M USD |
| Cost of goods sold | 129.37M USD | 111.05M USD | 112.56M USD | 261.44M USD | 228.8M USD |
| Gross profit | 298.17M USD | 194.4M USD | 90.01M USD | −26.75M USD | −16.6M USD |
| Research and development | 72.03M USD | 45.72M USD | 58.27M USD | 86.2M USD | 105.16M USD |
| Selling, general, and administrative | 239.22M USD | 168.48M USD | 194.71M USD | 338.24M USD | 318.73M USD |
| Operating expenses | 311.25M USD | 217.61M USD | 270.6M USD | 640.9M USD | 429.55M USD |
| Interest income | — | — | 1.11M USD | 2.54M USD | 79K USD |
| Interest expense | 2.54M USD | 3.03M USD | — | 3.21M USD | 2.84M USD |
| Depreciation and amortization | 25.22M USD | 21.95M USD | 33.73M USD | 59.31M USD | 21.81M USD |
| Operating income | −11.8M USD | −23.21M USD | −180.6M USD | −667.65M USD | −446.15M USD |
| Net income | −21.02M USD | −52.29M USD | −175.77M USD | −548.98M USD | −245.39M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK63.94M0.93%5.56B USD0.75%$87.60-0.79%
Vanguard Morningstar Total Stock Market ETFVTI51.55M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM36.02M0.05%77.7B USD0.19%$277.57-0.05%
ARK Genomic Revolution ETFARKG34.91M1.70%1.56B USD0.75%$49.29-1.70%
Vanguard Extended Market ETFVXF21.63M0.02%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO12.81M0.09%14.04B USD0.24%$353.47-0.53%
Thrivent Small-Mid Cap Equity ETFTSME10.81M1.21%895.7M USD0.65%$46.29-0.96%
Fidelity Enhanced Small Cap ETFFESM10.73M0.16%6.41B USD0.28%$45.25+0.07%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMARK Genomic Revolution ETFARKGVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOThrivent Small-Mid Cap Equity ETFTSMEFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
